Loading stock data...

Vanta Bioscience Limited

BSE: VANTABIO

BSE
22.01 0.00 (0.00%)

Prev Close

22.01

Open Price

22.15

Volume

6,000

Today Low / High

22.01 / 22.22

52 WK Low / High

16.26 / 31.95

Range

21 - 23

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 22.01, reflecting a change of 0 (0%). The expected target range on the BSE is 21 - 23. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.

20 Feb 22.15 -0.63%
19 Feb 20.30 0.00%
18 Feb 17.00 0.00%
17 Feb 16.26 0.00%
09 Feb 19.89 0.00%
08 Feb 19.89 0.00%

Vanta Bioscience Limited Graph

Vanta Bioscience Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Vanta Bioscience Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 22.01, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 22.01 22.23 20.01 - 24.45
22.45 17.96 - 26.94
22.67 15.87 - 29.47
Bearish Scenario 22.01 21.79 19.61 - 23.97
21.57 17.26 - 25.88
21.35 14.94 - 27.75

Overview of Vanta Bioscience Limited

ISIN

INE695X01011

Industry

Biotechnology

Vol.Avg

3,225

Market Cap

156,535,120

Last Dividend

0

Official Website

Visit Website

IPO Date

2017-10-06

DCF Diff

N/A

DCF

0

Financial Ratios Every Investor Needs

Stock Rating Details for VANTABIO

Metric Value Recommendation
Overall Rating C- Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 4 Buy

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 1.96 Cr 1.34 Cr 0.63 Cr 0.3201 0.00 Cr 0.00 Cr -8.67 Cr -4.77 Cr -7.56 -4.15 Cr -2.4317
2024-03-31 9.72 Cr 9.01 Cr 0.71 Cr 0.0732 0.00 Cr 5.00 Cr -3.18 Cr -2.32 Cr -3.67 1.42 Cr -0.2382
2023-03-31 5.83 Cr 7.16 Cr -1.33 Cr -0.2288 0.00 Cr 0.77 Cr -5.06 Cr -6.48 Cr -10.27 -1.71 Cr -1.1118
2022-03-31 9.39 Cr 4.80 Cr 4.60 Cr 0.4893 0.00 Cr 0.26 Cr 2.15 Cr 0.09 Cr 0.14 3.89 Cr 0.0094
2021-03-31 9.82 Cr 4.66 Cr 5.15 Cr 0.5251 0.00 Cr 0.26 Cr 2.75 Cr 0.45 Cr 0.71 3.97 Cr 0.0458

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.22 Cr 85.88 Cr 82.10 Cr 10.4240 Cr 70.08 Cr 69.86 Cr 6.51 Cr 23.96 Cr 0.00 Cr 0.00 Cr 0.00 Cr 26.5643 Cr
2024-03-31 0.16 Cr 85.40 Cr 72.42 Cr 15.1989 Cr 60.95 Cr 60.79 Cr 7.52 Cr 28.41 Cr 0.00 Cr 0.00 Cr 0.91 Cr 22.8768 Cr
2023-03-31 0.10 Cr 84.71 Cr 65.78 Cr 17.5147 Cr 57.16 Cr 57.06 Cr 7.16 Cr 33.23 Cr 0.00 Cr 0.00 Cr 0.91 Cr 17.7470 Cr
2022-03-31 0.22 Cr 81.40 Cr 52.06 Cr 24.0070 Cr 44.87 Cr 44.64 Cr 7.24 Cr 37.32 Cr 0.04 Cr 0.00 Cr 1.42 Cr 14.2785 Cr
2021-03-31 2.65 Cr 69.63 Cr 43.40 Cr 23.9188 Cr 35.97 Cr 33.32 Cr 9.76 Cr 34.86 Cr 0.06 Cr 0.00 Cr 0.00 Cr 14.8431 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 -2.4086 Cr -6.6935 Cr 9.1631 Cr -9.1021 Cr 0.0610 Cr 0.2216 Cr -6.6935 Cr -12.6289 Cr 9.1305 Cr 0.0000 Cr 1.0135 Cr
2024-03-31 2.6840 Cr -3.3132 Cr 0.6932 Cr -0.7207 Cr 0.0640 Cr 0.1606 Cr -3.4047 Cr -8.8266 Cr 3.7921 Cr 0.0000 Cr -0.3630 Cr
2023-03-31 -6.5135 Cr -5.9087 Cr 12.2946 Cr -35.2025 Cr -0.1276 Cr 0.0966 Cr -28.6890 Cr -6.4807 Cr 12.2946 Cr 0.0000 Cr 0.0780 Cr
2022-03-31 2.8753 Cr -17.1807 Cr 11.8793 Cr -14.3054 Cr -2.4261 Cr 0.2242 Cr -17.1807 Cr 0.0882 Cr 8.8970 Cr 0.0000 Cr 2.5287 Cr
2021-03-31 4.7291 Cr -22.1943 Cr 19.9204 Cr -17.4652 Cr 2.4552 Cr 2.6503 Cr -22.1943 Cr 0.4495 Cr 18.6004 Cr 0.0000 Cr 4.2431 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-09-30 0.30 Cr 0.45 Cr -0.15 Cr -0.4930 -0.98 Cr -1.82 Cr -2.56 -0.37 Cr -6.0268
2025-03-31 0.45 Cr 1.32 Cr -0.87 Cr -1.9464 -1.24 Cr -1.35 Cr -2.14 -1.96 Cr -3.0293
2024-12-31 0.45 Cr 1.32 Cr -0.87 Cr -1.9464 -1.24 Cr -1.35 Cr -2.14 -1.96 Cr -3.0293
2024-09-30 1.03 Cr 1.70 Cr -0.67 Cr -0.6534 -2.07 Cr -2.07 Cr -3.28 -0.34 Cr -2.0076
2024-06-30 0.54 Cr 0.65 Cr 1.18 Cr 2.2118 -0.77 Cr -1.03 Cr -1.64 -0.17 Cr -1.9329

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-09-30 0.15 Cr 0.00 Cr 0.15 Cr 1.82 Cr 7.73 Cr 11.15 Cr 10.28 Cr 56.86 Cr 37.62 Cr
2025-03-31 0.22 Cr 0.00 Cr 0.22 Cr 8.13 Cr 6.51 Cr 15.36 Cr 23.96 Cr 85.88 Cr 82.10 Cr
2024-12-31 0.22 Cr 0.00 Cr 0.22 Cr 2.50 Cr 6.51 Cr 15.36 Cr 23.96 Cr 85.88 Cr 82.10 Cr
2024-09-30 0.16 Cr 0.00 Cr 0.16 Cr 2.44 Cr 9.02 Cr 17.46 Cr 26.31 Cr 85.65 Cr 76.30 Cr
2024-06-30 0.16 Cr 0.00 Cr 0.16 Cr 2.44 Cr 9.02 Cr 17.46 Cr 26.31 Cr 85.65 Cr 76.30 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-09-30 -1.82 Cr -4.09 Cr 0.00 Cr 4.10 Cr -0.07 Cr 0.15 Cr 0.22 Cr 0.00 Cr -4.09 Cr
2025-03-31 -1.35 Cr -2.74 Cr -5.07 Cr 7.86 Cr 0.06 Cr 0.22 Cr 0.16 Cr -2.53 Cr -2.94 Cr
2024-12-31 -1.35 Cr -0.41 Cr -2.53 Cr 2.97 Cr 0.00 Cr 0.00 Cr 0.00 Cr -2.53 Cr -2.94 Cr
2024-09-30 -2.07 Cr -3.74 Cr -1.63 Cr 5.37 Cr 0.00 Cr 0.16 Cr 0.16 Cr -1.63 Cr -5.36 Cr
2024-06-30 -1.03 Cr -0.80 Cr -0.81 Cr 1.61 Cr 0.00 Cr 0.16 Cr 0.16 Cr -0.81 Cr -1.61 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Biotechnology

Company Name Symbol Price Market Cap Volume
Biocon Limited BIOCON ₹390.75 ₹495,927,671,088.00 ₹2,178,400.00
Anthem Biosciences Ltd. ANTHEM ₹697.50 ₹391,795,411,073.00 ₹171,457.00
Piramal Pharma Limited PPLPHARMA ₹159.48 ₹211,050,630,719.00 ₹2,655,138.00
Syngene International Limited SYNGENE ₹437.10 ₹175,605,704,786.00 ₹651,902.00
Onesource Specialty Pharma Ltd. ONESOURCE ₹1,322.90 ₹151,632,385,480.00 ₹176,072.00
Concord Biotech Limited CONCORDBIO ₹1,076.10 ₹112,577,497,124.00 ₹56,049.00
Jubilant Ingrevia Limited JUBLINGREA ₹602.45 ₹95,193,657,668.00 ₹169,531.00
Blue Jet Healthcare Limited BLUEJET ₹409.40 ₹71,016,744,995.00 ₹6,410,374.00
Supriya Lifescience Limited SUPRIYA ₹662.85 ₹53,348,023,980.00 ₹67,117.00
Zota Health Care Limited ZOTA ₹1,248.70 ₹37,876,386,299.00 ₹42,894.00
Dishman Carbogen Amcis Limited DCAL ₹179.06 ₹28,073,580,991.00 ₹225,009.00

Key Executives

MD & Director
Dopesh Raja Mulakala

Gender: male

Year Born: 1985

Vice President of HR & Admin
Mangesh Joshi

Gender: male

Year Born: 1966

Chief Financial Officer
Venkata Sathya Murali Dokka

Gender: male

Year Born: 1970

Head of QAU
Rajarajeswari Balaji

Gender: Not Specified

Year Born: 1978

Senior Vice President & TFM
Vadlamani Girish Shankar Shrma

Gender: Not Specified

Year Born: 1973

FAQs about Vanta Bioscience Limited

Who is the CEO of the company?

The CEO is Dopesh Raja Mulakala.

What is the current market price of the stock?

The current price is ₹22.01.

What is the 52-week price range?

The range is ₹16.26-31.95.

What is the market capitalization of the company?

The market capitalization is ₹15.65 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is -2.37.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Vanta Bioscience Limited (ISIN: INE695X01011) is a leading Biotechnology in India. With a market capitalization of ₹15.65 crores and an average daily volume of 3,225 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.